---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053653"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:46:19.515125+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa signs $50M upfront Roche collaboration for MGDs; MRT-2359 shows early efficacy

## Summary
- Upfront payment of $50M from Roche; potential milestones >$2B for initial oncology/neurology targets.
- Roche gains exclusive license after pre-clinical; Monte Rosa leads discovery on initial targets.
- MRT-2359 interim data: ~60% GSPT1 reduction in tumors; 2 partial responses in biomarker-positive patients.
- Safety profile supports further development; Grade 4 AEs at 2mg were transient, no discontinuations.
- Monte Rosa retains full ownership of pipeline; joint research committee governs collaboration.

## SEC filing metadata
- accession: 0000950170-23-053653
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/0000950170-23-053653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/glue-20231017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053653
- JSON: https://secwatch.observer/filing/0000950170-23-053653.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053653.txt

## Key facts
- Material Agreements
  Monte Rosa Therapeutics, Inc. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. valued at upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston (effective 2023-10-16).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
  - Value: upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston
  - Effective: 2023-10-16
  source text: On October 16, 2023, Monte Rosa Therapeutics AG (“Monte Rosa AG,” hereinafter the “Company”), a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc., F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US” and together with Roche Basel, “Roche”) entered into a Collaboration and License Agreement (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/0000950170-23-053653-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.